Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG4101 + Rituximab in R/R B-cell NHL
NCT03778619Phase 2Unknown
- Sponsor
- GC Cell
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MG4101 in B-cell non-Hodgkin lymphoma, sponsored by GC Cell. Status: unknown.
02
Drugs
MG4101
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03778619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778619.